👋 Hey, let’s get into it. AstraZeneca has reportedly spent recent months exploring a combination with Bristol Myers Squibb that would create a giant worth nearly $400 billion.

Nothing is signed, and the talks could still disappear into the same conference room where pharma keeps abandoned megadeals. But investors rendered an early verdict: AstraZeneca shares fell roughly 9% on Monday, while BMS barely moved.

BMS would bring U.S. scale and major franchises, including Eliquis and Opdivo, two blockbusters nearing loss of exclusivity. AstraZeneca shareholders are now trying to figure out how many “synergies” it takes to outrun two patent cliffs.

☢️ Curium Strikes an Up to $8B Deal for Lantheus
Curium agreed to buy Lantheus for $102.50 per share in cash at closing, with sales-linked contingent value rights worth up to another $12 per share. Altogether, the transaction could reach approximately $8 billion. The deal combines Curium’s isotope production and manufacturing network with Lantheus’s Pylarify imaging franchise and radioligand pipeline, creating a platform that stretches from isotope supply to patients across more than 70 countries. That vertical reach matters in radiopharma, where short shelf lives and limited manufacturing capacity can be as critical as the drug itself. The full $8 billion, however, depends on those sales milestones.

📉 Alnylam Loses $10.8B as Amvuttra Demand Normalizes
Alnylam trimmed its 2026 TTR product-revenue forecast from $4.4-$4.7 billion to $4.2-$4.5 billion as pent-up Amvuttra switch demand normalized. Investors responded by erasing about $10.8 billion in market value and driving shares down as much as 29%. The strange part is that the business is still booming: quarterly TTR revenue reached $1.03 billion, up 89%, with Amvuttra contributing $1.012 billion. Wall Street heard “normalization” and chose violence. The real concern is whether first-line patient starts can sustain the launch once the backlog is gone.

🧠 Supernus and Indivior Merge Into a $2.2B CNS Company
Supernus and Indivior agreed to an all-stock merger of equals that would create a CNS company with roughly $2.2 billion in annual revenue and 11 marketed medicines. Indivior shareholders would own 56.5% and receive a $1 billion special dividend before closing, while Supernus CEO Jack Khattar would lead the combined business. Management projects $125 million in annual savings and about $888 million in adjusted EBITDA, including synergies. It is called a merger of equals, though the ownership, leadership, and pre-closing checkbook are doing some interpretive work. Closing is targeted for the fourth quarter.

🫀 Novo’s Heart Drug Fails to Lower Cardiovascular Risk
Novo Nordisk’s ziltivekimab lowered the inflammation markers it was designed to hit in the more than 6,300-patient ZEUS trial. However, it did not lower heart attacks, strokes, or cardiovascular deaths. The Phase 3 study produced a MACE hazard ratio of 0.99, about as neutral as a result can get, while serious infections were more frequent with treatment. It is a sharp reminder that moving a biomarker does not guarantee moving a clinical outcome. Separate heart-failure and post-MI studies continue, with readouts expected in early 2027.

⛵️ J&J Puts $785M Behind Sail’s In Vivo CAR-T Bet
Johnson & Johnson committed $785 million in initial payments to collaborate with Sail Biomedicines on in vivo CAR-T programs for autoimmune disease, including a $465 million equity investment. Traditional CAR-T engineers a patient’s cells outside the body; Sail wants its RNA and targeted nanoparticles to reprogram T cells inside it, potentially removing much of the manufacturing marathon. The catch is considerable: the lead work remains preclinical. Sail can earn another $140 million in milestones, and J&J holds an exclusive option to buy the company for an additional $2.58 billion.

BioNucleus Briefing has 1,400+ combined newsletter subscriptions across email and LinkedIn, reaching scientists, founders, investors, operators, and other biotech and pharmaceutical professionals.

Sponsorship opportunities are available for companies offering tools, software, services, events, and other products relevant to the life-sciences industry.

Interested in sponsoring an upcoming issue? Reply to this email and let’s talk.

Alright, back to the newsletter.

🏭 Lilly and Resilience Put $750M Into U.S. GLP-1 Capacity
Lilly and Resilience will invest $750 million in Ohio GLP-1 device, fill-finish, and packaging capacity, adding at least 400 jobs by early 2027.

🤖 GSK Expands Relation AI Pact to $110M
GSK expanded its Relation Therapeutics collaboration to a potential $110 million, funding better human perturbation data to improve AI-driven target discovery.

🗳️ FDA Panel Backs Replimune’s RP1 in a 10–3 Vote
FDA advisers backed Replimune’s melanoma data 10–3 despite the agency’s lower response-rate analysis. A final FDA decision remained pending Monday morning.

🦠 Moderna’s Norovirus Vaccine Misses Its Interim Phase 3 Bar
Moderna’s norovirus vaccine missed its prespecified interim Phase 3 threshold, but the blinded trial continues with another cohort. This is extra innings, not game over.

🙌 FDA Gives Lilly’s Pancreatic Cancer Drug a Breakthrough Tag
FDA granted Lilly’s olomorasib Breakthrough Therapy designation for previously treated KRAS G12C pancreatic cancer, a mutation found in only 1%–2% of cases.

⚖️ Sandoz Pays $478.5M to Settle Generic Pricing Claims
Sandoz agreed to $478.5 million in settlements over alleged generic price-fixing. The company admitted no wrongdoing, proving generic drugs can still produce brand-name legal bills.

💰 Skyrizi Nearly Matches Humira’s Best-Ever Quarter
Skyrizi generated $5.5 billion last quarter, nearly matching Humira’s best-ever quarter. AbbVie now expects it to surpass Humira’s peak annual sales this year.

☢️ FDA Moves Novartis’ Pluvicto Into Hormone-Sensitive Prostate Cancer
FDA approved Pluvicto earlier in PSMA-positive metastatic prostate cancer after the combination cut progression-or-death risk 28%. Overall-survival data remain immature.

GLP-1s are no longer just remaking waistlines and pharma forecasts. They are building a second economy around everyone who can keep the drugs cold, move them quickly, prescribe them legally, and turn a monthly refill into a long-term customer.

Upstream, UPS, FedEx, DHL, and specialty logistics providers are investing in temperature-controlled facilities, validated packaging, and continuous monitoring. UPS alone is spending $48 million on 27 temperature-controlled cross-dock facilities across the Americas, Europe, and Asia. GLP-1s are one visible demand driver, alongside biologics, mRNA medicines, and cell and gene therapies. The obesity-drug boom did not invent the cold chain. It just handed it a very large new client.

Downstream, Amazon, Walmart, and Costco are competing for the patient relationship. Amazon One Medical combines clinical care with pharmacy fulfillment, while Amazon Pharmacy says cash-pay injectable options start at $299 per month and same-day delivery already reaches nearly 3,000 U.S. cities. Walmart is linking pharmacy, telehealth, nutrition, and refrigerated delivery. Costco is using member pricing to turn a prescription into another reason to visit the warehouse.

For retailers, the prize is not merely a dispensing fee. A recurring prescription can create years of healthcare spending, grocery trips, and data-rich customer contact. Independent pharmacies face the opposite math, with less purchasing power, fewer delivery resources, and considerably less room for a $1.50 hot dog loss leader.

The GLP-1 battle is no longer only Lilly versus Novo. It now includes everyone who stores, transports, prescribes, dispenses, and delivers the medicine.

Hear me out...Domino’s already has drivers, neighborhood locations, and the Pizza Tracker. Add licensed clinicians, validated cold storage, and a “prepare to lose your appetite” button, and the pivot deck practically writes itself.

That’s how many confirmed U.S. measles cases the CDC had reported through July 30, already above 2,289 in all of 2025 and the highest annual count since 1991. Ninety-four percent were outbreak-associated, while 93% involved unvaccinated people or those with unknown vaccination status.

Here’s what biotech Redditors are talking about:

😅 The 17-Month Biotech Job Search
An anonymous biotech operations professional finally landed a job after roughly 17 months and more than 1,000 applications. The new role offers a similar title and pay, but requires relocation to Boston and several office days each week. Their advice was refreshingly practical: tailor the resume, practice interviews, use your network, and set shame aside when asking for help. It is a deeply encouraging result, albeit from a single-participant study.

💸 Reddit Finds the “Synergies” in AstraZeneca-BMS Talks
Biotech Reddit translated the reported AstraZeneca-BMS talks into the industry’s preferred dialect: “synergies.” One commenter predicted “massive layoffs. Oh, I meant synergies,” while another said BMS had already been “synergized down to its last pipet.” A concerned BMS employee simply asked what the possibility could mean for staff. No deal or integration plan exists, but the thread showed how differently workers and merger advisers hear the exact same word.

🤖 FDA Clears DeepHealth’s AI Breast-Ultrasound Platform
FDA cleared DeepHealth’s AI breast-ultrasound platform, which RadNet plans to deploy after a company-reported study showed 8% higher sensitivity and 37% faster reads.

🔐 Amgen Cloud Breach Exposes Patient and Proprietary Data
Amgen says attackers stole patient health information and proprietary data from third-party clouds, with no detected impact on manufacturing or product supply.

🎥 MrBeast and Amgen Back Pediatric Cancer Research
Amgen joined MrBeast, Stand Up To Cancer, and St. Baldrick’s in a campaign announcing $6.5 million for pediatric cancer research.

⚖️ FTC Sues Hims & Hers Over Privacy and Billing Claims
FTC and state authorities allege Hims & Hers shared sensitive health data with advertising platforms and used deceptive billing; the company disputes the claims.

🪞 Mantis Wants to Build Your Digital Twin
Mantis Biotech is developing Parva, software designed to track changes in everyday typing and clicking against a person’s own baseline and flag potential cognitive shifts for clinical follow-up. The $7.4 million seed-funded startup is initially focusing on areas including ADHD, long COVID, dementia, and perimenopause, with a particular interest in women’s health. It is a clever premise, but still investigational. Browser activity is not yet a diagnosis, even if your 47 open tabs feel highly revealing.

🪦 August 4, 1997: The Longest Verified Human Life Ends at 122
On this day in 1997, Jeanne Calment died in Arles, France, at 122 years and 164 days old. She remains the oldest verified person ever and the only verified person to reach 120. Born in 1875, her life stretched from before the Eiffel Tower was finished to the early internet era. The longevity industry has since raised billions trying to extend healthy human life, but nearly three decades later, Calment’s record remains undefeated.

Thinking back to our GLP-1 supply-chain deep dive, the obesity-drug boom now has pharmacies, retailers, delivery companies, and cold-storage providers all chasing a piece of the market.

At this rate, Costco’s next expansion may skip the tire center completely and install a GLP-1 clinic between the rotisserie chickens and the $1.50 hot dogs. One suppresses your appetite; the other tests its resolve.

That’s all for today. See you Thursday for the next issue. 👋

✍️ Today’s email was brought to you by Josh Martin.

If you’re enjoying BioNucleus, share it with a friend or coworker who’d get value from it. We’re a small operation, and every share makes a bigger difference than you think.

Was this email forwarded to you? Sign up here 👇

Subscribe for free

Follow us on social and stay one step ahead